Is BDTX or ELYM more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Eliem Therapeutics N/A -47.03% -45.97%

Does the media refer more to BDTX or ARCT?

In the previous week, Arcturus Therapeutics had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Arcturus Therapeutics' score of 0.37 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, BDTX or PRTC?

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics $70M 1.61 $22.37M -$0.75 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is BDTX or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% PureTech Health N/A N/A N/A

Is BDTX or BNTC more profitable?

Benitec Biopharma's return on equity of -28.41% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Benitec Biopharma N/A -28.41% -27.76%

Does the media refer more to BDTX or BNTC?

In the previous week, Benitec Biopharma had 11 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 12 mentions for Benitec Biopharma and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Benitec Biopharma's score of 0.37 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CCCC or BDTX?

In the previous week, C4 Therapeutics and C4 Therapeutics both had 1 articles in the media. C4 Therapeutics' average media sentiment score of 1.34 beat Black Diamond Therapeutics' score of 0.76 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Diamond Therapeutics (BDTX) Competitors

$1.96 +0.03 (+1.55%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.26%)

As of 09/18/2026 07:46 PM Eastern

Compare

BDTX vs. ELYM, ARCT, PRTC, BNTC, and CCCC

Should you buy Black Diamond Therapeutics stock or one of its competitors? Black Diamond Therapeutics's main competitors and comparable companies include Eliem Therapeutics (ELYM), Arcturus Therapeutics (ARCT), PureTech Health (PRTC), Benitec Biopharma (BNTC), and C4 Therapeutics (CCCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Diamond Therapeutics compare to Eliem Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Black Diamond Therapeutics has a beta of 3.31, suggesting that its stock price is 231% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for Eliem Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Eliem Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Eliem Therapeutics	Neutral

Black Diamond Therapeutics' return on equity of -32.10% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Eliem Therapeutics	N/A	-47.03%	-45.97%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Black Diamond Therapeutics currently has a consensus price target of $10.25, indicating a potential upside of 422.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Black Diamond Therapeutics beats Eliem Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Arcturus Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Black Diamond Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 422.96%. Arcturus Therapeutics has a consensus target price of $23.00, suggesting a potential upside of 43.48%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Black Diamond Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Arcturus Therapeutics had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Arcturus Therapeutics' score of 0.37 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A
Arcturus Therapeutics	$82.03M	5.55	-$65.78M	-$3.31	N/A

Black Diamond Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Black Diamond Therapeutics' return on equity of -32.10% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Black Diamond Therapeutics has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Arcturus Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to PureTech Health?

Black Diamond Therapeutics (NASDAQ:BDTX) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Black Diamond Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 422.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Diamond Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for PureTech Health. Black Diamond Therapeutics' average media sentiment score of 0.76 beat PureTech Health's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
PureTech Health	Neutral

Black Diamond Therapeutics has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PureTech Health's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
PureTech Health	N/A	N/A	N/A

Summary

Black Diamond Therapeutics beats PureTech Health on 10 of the 13 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Benitec Biopharma?

Black Diamond Therapeutics (NASDAQ:BDTX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Benitec Biopharma had 11 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 12 mentions for Benitec Biopharma and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Benitec Biopharma's score of 0.37 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Black Diamond Therapeutics has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Benitec Biopharma's return on equity of -28.41% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Benitec Biopharma	N/A	-28.41%	-27.76%

Black Diamond Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 422.96%. Benitec Biopharma has a consensus target price of $24.00, indicating a potential upside of 117.79%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Black Diamond Therapeutics has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$0.98	N/A

Summary

Black Diamond Therapeutics beats Benitec Biopharma on 12 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. Black Diamond Therapeutics' return on equity of -32.10% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

C4 Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 126.16%. Black Diamond Therapeutics has a consensus price target of $10.25, indicating a potential upside of 422.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Black Diamond Therapeutics has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	11.60	-$104.99M	-$1.00	N/A
Black Diamond Therapeutics	$70M	1.61	$22.37M	-$0.75	N/A

In the previous week, C4 Therapeutics and C4 Therapeutics both had 1 articles in the media. C4 Therapeutics' average media sentiment score of 1.34 beat Black Diamond Therapeutics' score of 0.76 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats C4 Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.61M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.61	14.23	274.93	25.38
Price / Sales	1.61	1,419.61	646.01	89.45
Price / Cash	3.72	108.90	76.25	51.42
Price / Book	0.99	15.45	10.46	6.33
Net Income	$22.37M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.01%	-1.21%	0.59%	1.12%
1 Month Performance	-10.50%	-4.42%	-2.01%	-2.67%
1 Year Performance	-40.24%	37.81%	18.09%	6.01%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	2.9496 of 5 stars	$1.96 +1.6%	$10.25 +423.0%	-41.5%	$112.61M	$70M	N/A	21	High Trading Volume
ELYM Eliem Therapeutics	N/A	$14.95 -0.7%	N/A	+563.2%	$444.79M	N/A	N/A	9	High Trading Volume
ARCT Arcturus Therapeutics	2.9604 of 5 stars	$14.98 +7.2%	$23.00 +53.5%	-18.3%	$425.70M	$82.03M	N/A	180	News Coverage
PRTC PureTech Health	N/A	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
BNTC Benitec Biopharma	1.8019 of 5 stars	$12.19 -0.2%	$24.80 +103.4%	-21.2%	$418.73M	N/A	N/A	20	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. ELYM, ARCT, PRTC, BNTC, and CCCC

How does Black Diamond Therapeutics compare to Eliem Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Arcturus Therapeutics?

Summary

How does Black Diamond Therapeutics compare to PureTech Health?

Summary

How does Black Diamond Therapeutics compare to Benitec Biopharma?

Summary

How does Black Diamond Therapeutics compare to C4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. ELYM, ARCT, PRTC, BNTC, and CCCC

How does Black Diamond Therapeutics compare to Eliem Therapeutics?

Which has more risk & volatility, BDTX or ELYM?

Which has better valuation and earnings, BDTX or ELYM?

Does the media refer more to BDTX or ELYM?

Is BDTX or ELYM more profitable?

Do insiders & institutionals believe in BDTX or ELYM?

Do analysts prefer BDTX or ELYM?

Summary

How does Black Diamond Therapeutics compare to Arcturus Therapeutics?

Do analysts prefer BDTX or ARCT?

Does the media refer more to BDTX or ARCT?

Which has better earnings & valuation, BDTX or ARCT?

Is BDTX or ARCT more profitable?

Which has more risk & volatility, BDTX or ARCT?

Do institutionals & insiders hold more shares of BDTX or ARCT?

Summary

How does Black Diamond Therapeutics compare to PureTech Health?

Do analysts recommend BDTX or PRTC?

Which has preferable valuation & earnings, BDTX or PRTC?

Does the media refer more to BDTX or PRTC?

Which has more risk and volatility, BDTX or PRTC?

Do insiders & institutionals have more ownership in BDTX or PRTC?

Is BDTX or PRTC more profitable?

Summary

How does Black Diamond Therapeutics compare to Benitec Biopharma?

Does the media refer more to BDTX or BNTC?

Do institutionals and insiders have more ownership in BDTX or BNTC?

Which has more risk & volatility, BDTX or BNTC?

Is BDTX or BNTC more profitable?

Do analysts rate BDTX or BNTC?

Which has higher valuation and earnings, BDTX or BNTC?

Summary

How does Black Diamond Therapeutics compare to C4 Therapeutics?

Do institutionals & insiders believe in CCCC or BDTX?

Is CCCC or BDTX more profitable?

Do analysts rate CCCC or BDTX?

Which has higher valuation & earnings, CCCC or BDTX?

Does the media refer more to CCCC or BDTX?

Which has more risk & volatility, CCCC or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools